Contact

We scope to your needs across our three product lines—with fixed proposals and delivery timelines when scope is clear. Where engagements use the Open Targets Platform (and optional Orange Book or structure-informed layers), narratives stay traceable to public sources and updatable as data changes.

Pricing that fits the boardroom

We structure engagements so decision makers get predictable spend, clear deliverables, and no scope creep. No hourly surprises—you approve a fixed scope, price, and timeline up front when possible.

  • Fixed-fee, fixed-timeline — Agreed price and delivery date before work starts (when scope allows).
  • Entity-based scoping — Effort scales transparently with targets, diseases, drugs, or programs.
  • Product line — Scoped as Portfolio Intelligence, Visibility & Narrative, or Strategic Capital Options (see What we do).

How we scope

Fees and timeline follow your offer and entities. Open Targets–centric work traces to the Platform; Orange Book and structure-informed layers add scoped pulls under Portfolio Intelligence—see Structure-informed diligence.

Scope input What we need Typical use
Offer Portfolio Intelligence, Visibility & Narrative, or Strategic Capital Options Routes method and artifact
Target Per target (e.g. Ensembl ID) Single-target or multi-target intelligence
Disease / indication Per disease or indication set (e.g. EFO ID) Landscape, prioritisation
Drug Per drug or drug set Competitive or mechanism context
Portfolio N targets and/or N diseases Pipeline or portfolio review
Orange Book layer Approved products / comparators (search scope, date) Precedent vs listed drugs
Structure-informed layer Sequences / FASTA, monomer vs multimer Computational structural hypotheses — Structure-informed diligence

Bundle examples: Open Targets–only Portfolio Intelligence; Open Targets + Orange Book; Open Targets + Orange Book + structure-informed—one proposal, one synthesis.

Get in touch

Email: john@bioticabio.com

Next step

A short call to align on offer, decision question, and entities—then a written proposal with price and timeline.

Before reaching out: Portfolio Intelligence System and methodology.

Operator background · Diligence memo framework (legacy)

Our assessments are for strategic and due-diligence use only; they do not constitute regulatory, medical, or investment advice.

We use your contact details only to respond and do not share them with third parties.


About